Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Forrest

Showing results (51-60 of 177) with videos related to

Pageof 18
Sort By:
The Journal of Trauma|January 6, 2006
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patientsCurtis E Haas, Jamie L Nelsen, Krishnan Raghavendran, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2013
Reply to PaiCornelia B Landersdorfer, Roger L Nation, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|June 30, 2010
Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro modelPhillip J Bergen, Jurgen B Bulitta, Alan Forrest, et al.
The Journal of Infectious Diseases|December 17, 2009
Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypesPamela A Moise, Alan Forrest, Arnold S Bayer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2004
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapyPamela A Moise-Broder, George Sakoulas, George M Eliopoulos, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2008
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosaJürgen B Bulitta, Neang S Ly, Jenny C Yang, et al.
Journal of Intensive Care Medicine|June 11, 2008
A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patientsJamie L Nelsen, Curtis E Haas, Bahru Habtemariam, et al.
Plos One|June 11, 2016
Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachSamira M Garonzik, Justin R Lenhard, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Pageof 18

Showing results (51-60 of 177) with videos related to

Sort By:
Pageof 18
The Journal of Trauma|January 6, 2006
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patientsCurtis E Haas, Jamie L Nelsen, Krishnan Raghavendran, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2013
Reply to PaiCornelia B Landersdorfer, Roger L Nation, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|June 30, 2010
Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro modelPhillip J Bergen, Jurgen B Bulitta, Alan Forrest, et al.
The Journal of Infectious Diseases|December 17, 2009
Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypesPamela A Moise, Alan Forrest, Arnold S Bayer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2004
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapyPamela A Moise-Broder, George Sakoulas, George M Eliopoulos, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2008
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosaJürgen B Bulitta, Neang S Ly, Jenny C Yang, et al.
Journal of Intensive Care Medicine|June 11, 2008
A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patientsJamie L Nelsen, Curtis E Haas, Bahru Habtemariam, et al.
Plos One|June 11, 2016
Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachSamira M Garonzik, Justin R Lenhard, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Pageof 18